Text Size
115 studies found for:    "Acute promyelocytic leukemia"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Acute promyelocytic leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown † Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
2 Completed Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Promyelocytic Leukemia (M3);   Childhood Acute Promyelocytic Leukemia (M3);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: tretinoin;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: arsenic trioxide
3 Unknown † Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: NRX 195183 Soft Gelatin Capsule
4 Unknown † Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Single agent arsenic trioxide
5 Completed Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: AIDA
6 Active, not recruiting Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA;   Drug: Idarubicina;   Drug: Mitoxantrone;   Drug: ARA-C
7 Terminated Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Tamibarotene;   Drug: Arsenic trioxide
8 Withdrawn New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: NRX 195183 (retinoid analogue);   Drug: Arsenic Trioxide
9 Recruiting Autologous Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia After Relapse With Idarubicin and Busulfan Conditioning
Conditions: Acute Promyelocytic Leukemia;   Relapse
Intervention: Procedure: autologous hematopoietic cell transplantation
10 Recruiting Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic Trioxide;   Procedure: Autologous Transplantation;   Procedure: Allogenic Transplantation;   Drug: ATRA
11 Recruiting Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide
12 Unknown † AIDA 2000 Guidelines
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: all-trans retinoic acid (ATRA)
13 Active, not recruiting All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA);   Drug: Arsenic Trioxide (ATO);   Drug: Idarubicin
14 Completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Acute Promyelocytic Leukemia (M3);   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic bone marrow transplantation;   Drug: methylprednisolone;   Drug: methotrexate;   Drug: cyclosporine
15 Completed Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tamibarotene
16 Unknown † Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Disorders;   Acute Lymphocytic Leukemia;   Acute Promyelocytic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
17 Unknown † Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
18 Completed Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Condition: Leukemia
Intervention: Drug: arsenic trioxide
19 Withdrawn Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: homoharringtonine;   Procedure: chemotherapy
20 Completed Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: lintuzumab;   Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years